An internal standard for the quantification of digoxin
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Digoxin-d3

Item No. 10010657

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3β,5β,12β)-3-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide-21,21,22-d3
CAS Number
127299-95-0
Molecular Formula
C41H61D3O14
Formula Weight
784.0
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: SolubleMethanol: Slightly soluble
SMILES
C[C@@]12[C@@](CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]4(C)[C@]3(O)CC[C@@H]4C(C([2H])([2H])O5)=C([2H])C5=O)([H])C[C@@H](O[C@]6([H])O[C@H](C)[C@@H](O[C@@]7([H])C[C@H](O)[C@H](O[C@]8([H])O[C@H](C)[C@@H](O)[C@@H](O)C8)[C@@H](C)O7)[C@@H](O)C6)CC1
InChi Code
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1/i12D,18D2
InChi Key
LTMHDMANZUZIPE-JLCSYPFVSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $80

    Add

    1 mg

    $142

    Add

    5 mg

    $622

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Digoxin-d3 is intended for use as an internal standard for the quantification of digoxin (Item No. 22266) by GC- or LC-MS. Digoxin is a cardiac glycoside and metabolite of digitoxin (Item No. 27825) that binds to and inhibits the Na+/K+-ATPase in cardiac tissues in an ATP- and Mg2+-dependent manner.1 This inhibition results in loss of the transmembrane Na+ gradient, which decreases activity of the Na+/Ca2+ exchanger, increasing intracellular Ca2+ levels, inotropy, and cardiac force.2 It increases activity of mitochondrial ATPase and actomyosin ATPase in rat hearts, which is directly correlated with increased myofibrillar contractile strength.3 In vivo, digoxin also decreases right atrial pressure and increases cardiac output in a canine model of congestive heart failure produced by pulmonary artery constriction.4 Formulations containing digoxin have been used to treat atrial fibrillation.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Matsui, H., and Schwartz, A. Mechanism of cardiac glycoside inhibition of the (Na+-K+)-dependent ATPase from cardiac tissue. Biochim. Biophys. Acta 151(3), 655-663 (1968).

    2. Neves, C.H., Tibana, R.A., Prestes, J., et al. Digoxin induces cardiac hypertrophy without negative effects on cardiac function and physical performance in trained normotensive rats. Int. J. Sports Med. 38(4), 263-269 (2017).

    3. Hamrick, M.E., and Fritz, P.J. Enzymatic adaptation: Molecular basis for cardiac glycoside action? 1. Increase in rat heart actomyosin and mitochondrial ATPase specific activities following digoxin injection. Biochem. Biophys. Res. Commun. 22(5), 540-546 (1966).

    4. Davis, J.O., Howell, D.S., and Hyatt, R.E. Effects of acute and chronic digoxin administration in dogs with right-sided congestive heart failure produced by pulmonary artery constriction. Circ. Res. 3(3), 259-263 (1955).

    5. Kotecha, D., Calvert, M., Deeks, J.J., et al. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open 7(7), e015099 (2017).